This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.
This is a prospective, cohort study with no study investigational therapy prescribed. Patients with non-idiopathic pulmonary fibrosis (non-IPF) fibrosing ILD, including connective tissue disease associated ILD (CTD-ILD), fibrotic hypersensitivity pneumonitis (fHP) and non-IPF idiopathic interstitial pneumonia (IIP) will be recruited. Consented participants with non-IPF ILD will be carefully phenotyped with extensive clinical, physiological, and imaging data. After confirmation of eligibility, participants will undergo protocolized follow-up over 24 months. Clinical data and blood biospecimens will be collected at protocolized time points throughout the study. The primary outcome is 12-month transplant-free survival (TFS), following a 12-month observation period with TFS defined as the time from 12-month PFT to death, lung transplant or censoring at 12 months or earlier if lost to follow-up. This research will determine whether a ≥10% relative decline in FVC occurring during the 12-month observation period is associated with TFS over the subsequent 12 months. The investigators will then explore other proposed PPF criteria using the same approach. Additionally, the investigators will determine test performance characteristics of a novel proteomic biomarker for predicting PPF at 12 months and compare performance of this classifier to a multi-dimensional approach that incorporates clinical data and quantitative CT data.
Study Type
OBSERVATIONAL
Enrollment
500
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States
RECRUITINGUniversity of Michigan
Ann Arbor, Michigan, United States
RECRUITINGUniversity of Texas Southwestern
Dallas, Texas, United States
NOT_YET_RECRUITINGUniversity of Virginia
Charlottesville, Virginia, United States
NOT_YET_RECRUITINGUniversity of Washington
Seattle, Washington, United States
NOT_YET_RECRUITINGRoyal Prince Alfred Hospital
Camperdown, New South Wales, Australia
NOT_YET_RECRUITINGPrince Charles Hospital
Brisbane, Queensland, Australia
NOT_YET_RECRUITINGAustin Health
Melbourne, Victoria, Australia
NOT_YET_RECRUITINGUniversity of Calgary
Calgary, Alberta, Canada
NOT_YET_RECRUITINGUniversity of British Columbia
Vancouver, British Columbia, Canada
NOT_YET_RECRUITING...and 3 more locations
Transplant-free survival (TFS)
TFS is defined as the time from the 12-month pulmonary function tests to death or lung transplant. Censoring will occur at 12-months or earlier if lost to follow-up.
Time frame: 12-months to 24-months (following an observation period from 0 months to 12 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.